- HK$9.73bn
- HK$13.32bn
- CNY6.14bn
- 39
- 69
- 16
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 14.35 | ||
| PEG Ratio (f) | 1.01 | ||
| EPS Growth (f) | 16.51% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.72 | ||
| Price to Tang. Book | 1.74 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.46 | ||
| EV to EBITDA | 6.19 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.92% | ||
| Return on Equity | 4.69% | ||
| Operating Margin | 22.38% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 6,357.85 | 5,539.64 | 5,200.23 | 5,981.66 | 6,143.08 | 6,830.8 | 7,805.88 | 3.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +6.39 | -48.66 | -95.28 | +1727.18 | -23.85 | +14.16 | +21.69 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Company’s main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimer’s disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The Company operates its business mainly in Mainland China.
Directors
- Dian Bo Liu CHM (55)
- Rong Bing Yang VCH (55)
- Yuan Chong Liu CFO (57)
- You Xin Li SVP (59)
- Yun Li Xue SVP (57)
- Hui Xian Yuan EDR (62)
- Yuan Yuan Zhu EDR (40)
- Mei Yi Lee SEC
- Rui Lin Song NED (59)
- Xin Sun NED (40)
- Sze Chung Choy NID (62)
- Man Kit Leung NID (67)
- Yuk Lam Lo NID (71)
- Hua Qiao Zhang NID (57)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 2nd, 2003
- Public Since
- July 9th, 2014
- No. of Employees
- 5,005
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Stock Exchange of Hong Kong Limited- Shares in Issue
- 3,549,670,643
- Address
- No.15 Chuangye Road, High-Tech Zone, YANTAI, 264003
- Web
- https://www.luye.cn/lvye/
- Phone
- +86 5356717618
- Auditors
- Ernst & Young
Upcoming Events for 2186
Similar to 2186
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:13 UTC, shares in Luye Pharma are trading at HK$2.74. This share price information is delayed by 15 minutes.
Shares in Luye Pharma last closed at HK$2.74 and the price had moved by -31.5% over the past 365 days. In terms of relative price strength the Luye Pharma share price has underperformed the FTSE Developed Asia Pacific Index by -31.03% over the past year.
The overall consensus recommendation for Luye Pharma is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Luye Pharma does not currently pay a dividend.
Luye Pharma does not currently pay a dividend.
Luye Pharma does not currently pay a dividend.
To buy shares in Luye Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$2.74, shares in Luye Pharma had a market capitalisation of HK$9.73bn.
Here are the trading details for Luye Pharma:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2186
Based on an overall assessment of its quality, value and momentum Luye Pharma is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Luye Pharma is HK$3.02. That is 10.27% above the last closing price of HK$2.74.
Analysts covering Luye Pharma currently have a consensus Earnings Per Share (EPS) forecast of CNY0.17 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Luye Pharma. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -29.81%.
As of the last closing price of HK$2.74, shares in Luye Pharma were trading -17.01% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Luye Pharma PE ratio based on its reported earnings over the past 12 months is 14.35. The shares last closed at HK$2.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Luye Pharma's management team is headed by:
- Dian Bo Liu - CHM
- Rong Bing Yang - VCH
- Yuan Chong Liu - CFO
- You Xin Li - SVP
- Yun Li Xue - SVP
- Hui Xian Yuan - EDR
- Yuan Yuan Zhu - EDR
- Mei Yi Lee - SEC
- Rui Lin Song - NED
- Xin Sun - NED
- Sze Chung Choy - NID
- Man Kit Leung - NID
- Yuk Lam Lo - NID
- Hua Qiao Zhang - NID